Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Erasca, Inc. (ERAS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.22-1.53 (-7.75%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close19.75
Open19.79
Bid16.00 x 800
Ask20.00 x 800
Day's Range18.11 - 19.96
52 Week Range14.51 - 24.47
Volume116,044
Avg. Volume336,825
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.50
  • GlobeNewswire

    Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference

    SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Evercore ISI 4th Annual HealthCONx Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a “Fireside Chat” beginning at 3:05

  • GlobeNewswire

    Erasca Reports Third Quarter 2021 Financial Results and Business Updates

    Strong execution leading to four ongoing clinical trials evaluating lead candidates ERAS-007 (ERKi) and ERAS-601 (SHP2i) Named one of Fierce Biotech’s “Fierce 15” most promising biotechnology companies of 2021 Donated $17.5 million of common shares to the Erasca Foundation to fund mission-related charitable activities Robust balance sheet with cash of $487 million SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focu

  • GlobeNewswire

    Erasca Announces Presentation of Preclinical Data on ERAS-801, a CNS-Penetrant EGFR Inhibitor with Broad Activity against Oncogenic EGFR Alterations, at AACR Conference on Brain Cancer

    ERAS-801's CNS penetration: four times higher than approved EGFR inhibitorsComprehensive inhibition against oncogenic EGFR vIII and wildtype alterationsImproved outcomes in over 90% of EGFR-driven patient-derived glioblastoma modelsIND submission in refractory glioblastoma planned for Q1 2022 SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patient

Advertisement
Advertisement